Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 2/20 | 0.32 |
| ▸ | JAK1 | P23458 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18950459 | 0.82 | GPR119 (0.36) | GPR119FAAH | |
| SCHEMBL4145435 | 0.82 | GPR119 (0.36) | GPR119NR1H2FAAH | |
| SCHEMBL2800325 | 0.81 | GPR119 (0.35) | GPR119MEN1KMT2AFAAH | |
| SCHEMBL2490063 | 0.81 | FAAH (0.43) | GPR119MEN1ALDH1A1KMT2AFAAH | |
| SCHEMBL27746941 | 0.79 | CYP2C9 (0.47) | GPR119FAAH | |
| SCHEMBL6172065 | 0.79 | GPR119 (0.35) | GPR119NR1H2ALDH1A1FAAH | |
| SCHEMBL6555078 | 0.79 | L3MBTL1 (0.35) | GPR119ALDH1A1FAAH | |
| SCHEMBL7283194 | 0.79 | GPR119 (0.33) | GPR119CTSKFAAH | |
| SCHEMBL20759177 | 0.78 | CPB2 (0.39) | GPR119MEN1KMT2AFAAH | |
| SCHEMBL31326623 | 0.78 | FAAH (0.35) | GPR119NR1H2MEN1KMT2AFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040171844-A1 | Dihydro-2H-naphthalene-1-one inhibitors of ras farnesyl transferase | LEONARD DANIELE MARIE (US) | 2004-09-02 | — | — | US | disclosed |
| US-20040063770-A1 | Method for treating Alzheimer's disease | WARNER-LAMBERT COMPANY | 2004-04-01 | — | — | US | disclosed |
| US-20030232790-A1 | Dihydro-2h-napthalene-1-one inhibitors of ras farnesyl transferase | WARNER-LAMBERT COMPANY | 2003-12-18 | — | — | US | disclosed |
| EP-1276724-A2 | DIHYDRO-2H-NAPHTHALENE-1-ONE INHIBITORS OF RAS FARNESYL TRANSFERASE | WARNER-LAMBERT COMPANY (US) | 2003-01-22 | — | — | EP | disclosed |
| US-20010051642-A1 | Method for treating Alzheimer's disease | AHN KYUNGHYE (US) | 2001-12-13 | — | — | US | disclosed |
| WO-2001079179-A2 | DIHYDRO-2H-NAPHTHALENE-1-ONE INHIBITORS OF RAS FARNESYL TRANSFERASE | WARNER-LAMBERT COMPANY (US) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171844-A1 | Dihydro-2H-naphthalene-1-one inhibitors of ras farnesyl transferase | NRAS, HRAS, FNTB | GPR119 701/4885NR1H2 5/4885CTSK 2594/4885 |
| US-20040063770-A1 | Method for treating Alzheimer's disease | BACE1, BACE2, PSEN1 | GPR119 1105/4885NR1H2 14/4885CTSK 1427/4885 |
| US-20010051642-A1 | Method for treating Alzheimer's disease | BACE1, BACE2, PSEN1 | GPR119 1105/4885NR1H2 14/4885CTSK 1427/4885 |
| US-20030232790-A1 | Dihydro-2h-napthalene-1-one inhibitors of ras farnesyl transferase | NRAS, FNTA, CYP46A1 | GPR119 2510/4885NR1H2 31/4885CTSK 1529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.